Pharmacokinetics of nalidixinic acid and oxolinic acid in healthy women
- PMID: 1245092
- DOI: 10.1002/cpt197619137
Pharmacokinetics of nalidixinic acid and oxolinic acid in healthy women
Abstract
The pharmacokinetics of oral nalidixic acid (NA, 1 gm 4 times a day) and oxolinic acid (OA, 750 mg 2 times a day) administered for 7 days were studied in the same 10 healthy women on the first, third, and seventh days of the treatment. The peak concentrations of NA + OH-NA (hydroxynalidixinic acid) in serum at 2 to 3 hr were 34 mug/ml (total) and 23 mug/ml (unconjugated) on the first day and nearly two times higher on the third and seventh days; 82% to 85% of these amounts were NA. The protein-free fraction of NA + OH-NA was 8.8% to 18.3%. The total concentration of NA + OH-NA in urine was 1,220 to 2,700 mug/ml, the unconjugated concentration, 250 to 350 mug/ml, and the chemotherapeutically active concentration, 55 to 75 mug/ml. In steady state the 24-hr recovery of the total drug was 79% of the daily dose. The excretion rate in urine was 591 to 853 mg/6 hr. The OA concentration in serum was very low on the first day of the treatment, but increased to 4- to 5-fold on the third and seventh days: 6.2 to 6.4 mug/ml (total) and 3.3 to 3.6 mug/ml (unconjugated). The protein-free OA represented 19% to 23% of the total amount. The modest initial serum concentrations of OA were confirmed by the low urine concentrations on the first day. In steady state the OA concentration in urine was 570 mug/ml (total) and 35 mug/ml (unconjugated), and the 24-hr recovery, 49% and 3%, respectively. The microbiologic assay gave somewhat higher concentrations of the active drug than did the chemical assay. When taken with food, the excretion of OA in urine was retarded by 6 hr but the 48-hr recovery was not decreased.
Similar articles
-
Nalidixic acid kinetics after single and repeated oral doses.Clin Pharmacol Ther. 1981 May;29(5):695-8. doi: 10.1038/clpt.1981.97. Clin Pharmacol Ther. 1981. PMID: 7214799
-
Pharmacokinetics of nalidixic acid associated with sodium citrate.Biopharm Drug Dispos. 1984 Jul-Sep;5(3):211-8. doi: 10.1002/bdd.2510050303. Biopharm Drug Dispos. 1984. PMID: 6487750
-
Clinical pharmacology of oxolinic acid in young dairy calves.Am J Vet Res. 1976 May;37(5):513-6. Am J Vet Res. 1976. PMID: 776048
-
Drug therapy reviews: nalidixic acid.Am J Hosp Pharm. 1979 Aug;36(8):1071-6. Am J Hosp Pharm. 1979. PMID: 384787 Review. No abstract available.
-
Drug therapy reviews: oxolinic acid.Am J Hosp Pharm. 1979 Aug;36(8):1077-9. Am J Hosp Pharm. 1979. PMID: 384788 Review. No abstract available.
Cited by
-
Minimal inhibitory concentrations of 19 antimicrobial agents for 96 clinical isolates of group IVe bacteria.Antimicrob Agents Chemother. 1983 Sep;24(3):432-3. doi: 10.1128/AAC.24.3.432. Antimicrob Agents Chemother. 1983. PMID: 6638999 Free PMC article.
-
The place of quinolones in antibacterial therapy in hospitals.Pharm Weekbl Sci. 1986 Feb 21;8(1):72-8. doi: 10.1007/BF01975485. Pharm Weekbl Sci. 1986. PMID: 3960694
-
Experiences on the efficacy and safety of nalidixic acid, oxolinic acid, cinoxacin and norfloxacin in the treatment of urinary tract infections (UTI).Infection. 1984 Nov-Dec;12(6):377-80. doi: 10.1007/BF01645218. Infection. 1984. PMID: 6240470 Clinical Trial.
-
Single- and multiple-dose pharmacokinetics of pipemidic acid in normal human volunteers.Antimicrob Agents Chemother. 1984 Jul;26(1):69-73. doi: 10.1128/AAC.26.1.69. Antimicrob Agents Chemother. 1984. PMID: 6476816 Free PMC article.
-
Pharmacokinetics of nalidixic acid in man: hydroxylation and glucuronidation.Pharm Weekbl Sci. 1988 Oct 14;10(5):193-9. doi: 10.1007/BF01956870. Pharm Weekbl Sci. 1988. PMID: 3205675